Tom 9, Nr 5 (2015)
Wybrane problemy kliniczne
Opublikowany online: 2015-11-30
Wyświetlenia strony
2538
Wyświetlenia/pobrania artykułu
45204
Rekomendacje Polskiego Towarzystwa Nefrologii Dziecięcej (PTNFD) dotyczące postępowania z dzieckiem z podwyższonym ciśnieniem tętniczym
Forum Medycyny Rodzinnej 2015;9(5):349-375.
Streszczenie
Brak
Referencje
- GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015; 385(9963): 117–171.
- Seshadri S, Beiser A, Kelly-Hayes M, et al. The lifetime risk of stroke: estimates from the Framingham Study. Stroke. 2006; 37(2): 345–350.
- Ryglewicz D, Milewska D. Epidemiologia udaru mózgu. In: Mazur R, Książkiewicz B, Nyka WM. ed. Udar mózgu w praktyce lekarskiej. Via Medica, Gdańsk 2010: 5–14.
- Kobayashi A, Czlonkowska A, Ahmed N, et al. SITS Poland Collaborative Group. Intravenous recombinant tissue plasminogen activator for acute stroke in Poland: an analysis based on the Safe Implementation of Thrombolysis in Stroke (SITS) Registry. Acta Neurol Scand. 2010; 122: 229–236.
- Dziedzic T. Etiologia udaru mózgu. In: Szczudlik A, Członkowska A, Kwieciński H. ed. Udar Mózgu. Uniwersytetu Jagiellońskiego, Kraków 2007: 97.
- Antoniades C, Bakogiannis C, Tousoulis D, et al. Platelet activation in atherogenesis associated with low-grade inflammation. Inflamm Allergy Drug Targets. 2010; 9(5): 334–345.
- Jurk K, Kehrel BE. Pathophysiology and biochemistry of platelets. Internist (Berl). 2010; 51(9): 1088–1094.
- Massberg S, Schulz C, Gawaz M. Role of platelets in the pathophysiology of acute coronary syndrome. Semin Vasc Med. 2003; 3(2): 147–162.
- Linden MD, Jackson DE. Platelets: pleiotropic roles in atherogenesis and atherothrombosis. Int J Biochem Cell Biol. 2010; 42(11): 1762–1766.
- Thomson RM, Anderson DC. Aspirin and clopidogrel for prevention of ischemic stroke. Curr Neurol Neurosci Rep. 2013; 13(2): 327.
- Cevik O, Adiguzel Z, Baykal AT, et al. The apoptotic actions of platelets in acute ischemic stroke. Mol Biol Rep. 2013; 40(12): 6721–6727.
- Lavallée PC, Labreuche J, Faille D, et al. Lacunar-B.I.C.H.A.T. Investigators. Circulating markers of endothelial dysfunction and platelet activation in patients with severe symptomatic cerebral small vessel disease. Cerebrovasc Dis. 2013; 36(2): 131–138.
- Hopkins PN. Molecular biology of atherosclerosis. Physiol Rev. 2013; 93(3): 1317–1542.
- Freson K, Thys C, Wittevrongel C, et al. Mechanisms of action and targets for actual and future antiplatelet drugs. Mini Rev Med Chem. 2006; 6(6): 719–726.
- Dudek D, Filipiak KJ, Stępińska J. Ostry zespół wieńcowy. Jak leczyć skuteczniej i szybciej. Doustne leki przeciwpłytkowe. Termedia, Poznań 2006.
- McTavish D, Faulds D, Goa KL. Ticlopidine. An updated review of its pharmacology and therapeutic use in platelet-dependent disorders. Drugs. 1990; 40(2): 238–259.
- Tirschwell D. Aspirin plus dipyridamole was more effective than aspirin alone for preventing vascular events after minor cerebral ischemia. ACP J Club. 2006; 145(3): 57.
- Kubica J, Koziński M, Grześk G. Mechanizmy działania leków przeciwpłytkowych. Folia Cardiologica Experta. 2009 ; 4(12).
- International Stroke Trial Collaborative Group. The International Stroke Trial. Lancet. (349): 1569–1581.
- Chinese Acute Stroke Trial ( CAST). Lancet. 1999; 349: 1641–1649.
- Jauch EC, Saver JL, Adams HP, et al. American Heart Association Stroke Council, Council on Cardiovascular Nursing, Council on Peripheral Vascular Disease, Council on Clinical Cardiology. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013; 44(3): 870–947.
- Wytyczne grupy ekspertów sekcji chorób naczyniowych PTN. Neurologia i Neurochirurgia Polska. 2012; 46(supl.1): 63–64.
- Kernan WN, Ovbiagele B, Black HR, et al. American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, and Council on Peripheral Vascular Disease. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014; 45(7): 2160–2236.
- Lee YS, Bae HJ, Kang DW, et al. Cilostazol in Acute Ischemic Stroke Treatment (CAIST Trial): A Randomized Double-Blind Non-Inferiority Trial. Cerebrovascular Diseases. 2011; 32(1): 65–71.
- Powers WJ, Rabinstein AA, Ackerson T, et al. American Heart Association Stroke Council. 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2018; 49(3): e46–e4e110.
- Shinohara Y, Nishimaru K, Sawada T, et al. S-ACCESS Study Group. Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS): A randomized, double-blind, aspirin-controlled trial. Stroke. 2008; 39(6): 1827–1833.
- Bousser MG, Amarenco P, Chamorro A, et al. PERFORM Study Investigators. Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial. Lancet. 2011; 377(9782): 2013–2022.
- Kwok CS, Shoamanesh A, Copley HC, et al. Efficacy of antiplatelet therapy in secondary prevention following lacunar stroke: pooled analysis of randomized trials. Stroke. 2015; 46(4): 1014–1023.
- Asdaghi N, Romano JG. Dual antiplatelet therapy in acute ischemic stroke. Journal of Neurology. 2016; 263(11): 2247–2259.
- Benavente OR, Hart RG, McClure LA. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N Engl J Med. 2012; 366: 817–825.
- Diener HC, Bogousslavsky J, Brass LM, et al. MATCH investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet. 2004; 364(9431): 331–337.
- Winningham M, Kasshout T, Bamford L. The optimal duration of dual antiplatelet therapy after PCI. Stroke. 2015; 46(Suppl 1).
- Markus HS, Droste DW, Kaps M, et al. Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial. Circulation. 2005; 111(17): 2233–2240.
- Jones DW, Goodney PP, Conrad MF, et al. Dual antiplatelet therapy reduces stroke but increases bleeding at the time of carotid endarterectomy. J Vasc Surg. 2016; 63(5): 1262–1270.e3.
- Batchelder A, Hunter J, Cairns V, et al. Dual Antiplatelet Therapy Prior to Expedited Carotid Surgery Reduces Recurrent Events Prior to Surgery without Significantly Increasing Peri-operative Bleeding Complications. Eur J Vasc Endovasc Surg. 2015; 50(4): 412–419.
- Niaz A, Steiner T, Caso V. Recommendations from the ESO-Karolinska Stroke Update Conference, Stockholm 13–15 November 2016. European Stroke Journal. 2017: 1–8.
- Watała C, Golański J. Fizjologiczne i molekularne mechanizmy oporności na kwas acetylosalicylowy. Kardiol Dypl. 2005; 2: 16–20.
- Golański J, Chłopicki S, Golański R, et al. Resistance to aspirin in patients after coronary artery bypass grafting is transient: impact on the monitoring of aspirin antiplatelet therapy. Ther Drug Monit. 2005; 27(4): 484–490.
- Altman R, Luciardi HL, Muntaner J, et al. The antithrombotic profile of aspirin. Aspirin resistance, or simply failure? Thromb J. 2004; 2(1): 1.
- Postuła M, Kapłon A. Oporność na kwas acetylosalicylowy i jego kliniczne znaczenie. Kardiologia w praktyce. 2007; 3(3): 144–152.
- Kamińska M, Musiał WJ, Osada J, et al. Problem „oporności” na leki przeciwpłytkowe. Terapia Kardiodiabetologia. 2009; 4: 28–33.
- Kour D, Tandon V, Kapoor B, et al. Aspirin Resistance. New Hor. 2006; 41: 116–117.
- Alberts MJ, Bergman DL, Molner E, et al. Antiplatelet effect of aspirin in patients with cerebrovascular disease. Stroke. 2004; 35(1): 175–178.
- Jastrzębska M, Siennicka A, Chełstowski K, et al. Laboratoryjna ocena odpowiedzi na leczenie kwasem acetylosalicylowym (ASA) u pacjentów w ostrej fazie udaru niedokrwiennego mózgu – zastosowanie agregometrii przepływowej (PFA-100) i impedancyjnej (Multiplate). J of Lab Diagn. 2011; 47(2): 155–163.
- Krishnan K, Beridze M, Christensen H, et al. TARDIS Trial Investigators. Safety and efficacy of intensive vs. guideline antiplatelet therapy in high-risk patients with recent ischemic stroke or transient ischemic attack: rationale and design of the Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke (TARDIS) trial (ISRCTN47823388). Int J Stroke. 2015; 10(7): 1159–1165.
- Wang Y, Wang Y, Zhao X. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med. 2013; 369(11): 19.
- Liu Y, Fei Z, Wang W, et al. Efficacy and safety of short-term dual- versus mono-antiplatelet therapy in patients with ischemic stroke or TIA: a meta-analysis of 10 randomized controlled trials. J Neurol. 2016; 263(11): 2247–2259.
- Amarenco P, Albers GW, Denison H. Steering Committee and Investigators. Efficacy and safety of ticagrelor versus aspirin in acute stroke or transient ischaemic attack of atherosclerotic origin: a subgroup analysis of SOCRATES, a randomised, double-blind, controlled trial. Lancet Neurol. 2017; 16(301): 310.
- Bonaca MP, Goto S, Bhatt DL, et al. Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54). Circulation. 2016; 134(12): 861–871.
